JP2011148741A - Slimming composition - Google Patents
Slimming composition Download PDFInfo
- Publication number
- JP2011148741A JP2011148741A JP2010012156A JP2010012156A JP2011148741A JP 2011148741 A JP2011148741 A JP 2011148741A JP 2010012156 A JP2010012156 A JP 2010012156A JP 2010012156 A JP2010012156 A JP 2010012156A JP 2011148741 A JP2011148741 A JP 2011148741A
- Authority
- JP
- Japan
- Prior art keywords
- fucoxanthin
- extract
- gymnema
- slimming
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 claims abstract description 38
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 claims abstract description 38
- 241000208251 Gymnema Species 0.000 claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 17
- 241000199919 Phaeophyceae Species 0.000 claims abstract description 12
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 11
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 10
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 10
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 10
- 241000282553 Macaca Species 0.000 claims description 2
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 abstract description 15
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 7
- 241000015177 Saccharina japonica Species 0.000 abstract description 2
- 210000000593 adipose tissue white Anatomy 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 235000020737 peppermint extract Nutrition 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- -1 ethylene, propylene, ethanol Chemical class 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241001261506 Undaria pinnatifida Species 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000000636 white adipocyte Anatomy 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 241000199899 Alariaceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000980780 Cladosiphon okamuranus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000243681 Eisenia bicyclis Species 0.000 description 1
- 241000980789 Eudesme virescens Species 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241001466452 Laminariaceae Species 0.000 description 1
- 240000007707 Mentha arvensis Species 0.000 description 1
- 235000018978 Mentha arvensis Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 241001479543 Mentha x piperita Species 0.000 description 1
- 235000002852 Olea africana Nutrition 0.000 description 1
- 244000061775 Olea africana Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000195475 Sargassaceae Species 0.000 description 1
- 241000195473 Sargassum fulvellum Species 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 235000021027 japanese diet Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001771 mentha piperita Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
痩身効果が相乗的に向上した痩身用組成物に関する。 The present invention relates to a slimming composition in which the slimming effect is synergistically improved.
日本人の食事は、近年著しく欧米化し、高カロリー化が進んでいる。特に、脂質の過剰摂取が現代の文明病とも言われている肥満を引き起こしている。また、肥満は、高脂血症、動脈硬化、糖尿病等、種々の疾病と密接に関連しているため社会問題の一つとなっている。また、近年の日本人の美意識に痩せたいという願望が極めて強くなってきている。 In recent years, Japanese diets have become significantly westernized and high-calorie is progressing. In particular, excessive intake of lipids causes obesity, which is also called modern civilization. Obesity is one of the social problems because it is closely related to various diseases such as hyperlipidemia, arteriosclerosis and diabetes. In addition, the desire to become obsessed with Japanese aesthetics in recent years has become extremely strong.
フコキサンチンは、褐藻類、特にコンブに多く含まれるカロテノイドの一種である。このフコキサンチンが、通常は褐色脂肪細胞に特異的に存在するタンパク質であるサーモゲニン（Thermogenin；熱産生タンパク質）のＵＣＰ１（uncoupling protein 1）の発現を白色脂肪細胞において促すことで、脂肪組織における脂肪の燃焼を助けること（非特許文献１参照）、中性脂肪の吸収を調整すること（特許文献１参照）が知られており、痩身効果が期待される素材である。 Fucoxanthin is a kind of carotenoid that is abundant in brown algae, especially kombu. This fucoxanthin promotes the expression of UCP1 (uncoupling protein 1) of thermogenin (thermogenin), a protein normally present in brown adipocytes, in white adipocytes. It is known to assist combustion (see Non-Patent Document 1) and to adjust the absorption of neutral fat (see Patent Document 1), and is a material expected to have a slimming effect.
しかしながら、化学合成や遺伝子組換などの手法によるフコキサンチンの生産が現在のところ不可能なため、供給源が褐藻のみであること、加えて褐藻中に含まれるフコキサンチン量は、多いものでも乾燥重量の0.1%程度であるため、フコキサンチンのみを有効量痩身用組成物に配合するのは困難な状況であった。そこで、本発明においては、フコキサンチンによる白色細胞におけるＵＣＰ１の発現を相乗的に向上させ、高い痩身効果を発揮する痩身用組成物を提供することを目的とした。 However, production of fucoxanthin by methods such as chemical synthesis and genetic recombination is currently impossible, so the source is only brown algae, and in addition, even if the amount of fucoxanthin contained in brown algae is large, it is dry Since it is about 0.1% of the weight, it was difficult to blend only an effective amount of fucoxanthin into the slimming composition. Therefore, an object of the present invention is to provide a slimming composition that synergistically improves the expression of UCP1 in white cells by fucoxanthin and exhibits a high slimming effect.
本願の第一の発明は、成分（Ａ）フコキサンチンと、成分（Ｂ）ギムネマ及び／又はペパーミントを含有してなる痩身用組成物に関する。 The first invention of the present application relates to a slimming composition comprising component (A) fucoxanthin and component (B) gymnema and / or peppermint.
本願の第ニの発明は、成分（Ａ）フコキサンチンを含有する褐藻類から選択される１種又は２種以上と、成分（Ｂ）ギムネマ及び／又はペパーミントを含有してなる痩身用組成物に関する。 The second invention of the present application relates to a slimming composition comprising one or more selected from brown algae containing component (A) fucoxanthin and component (B) gymnema and / or peppermint. .
本願の第三の発明は、成分（Ａ）フコキサンチンを含有するマコンブ抽出物と、成分（Ｂ）ギムネマ及び／又はペパーミントを含有してなる痩身用組成物に関する。 The third invention of the present application relates to a slimming composition comprising a macaque extract containing component (A) fucoxanthin and a component (B) gymnema and / or peppermint.
本発明の痩身用組成物は、成分（Ａ）フコキサンチン及びフコキサンチンを含有する褐藻類と、成分（Ｂ）ギムネマ及び／又はペパーミントを併用して用いることにより、フコキサンチンによる白色細胞におけるＵＣＰ１の発現が相乗的に向上し、高い痩身効果を発揮する。 The slimming composition of the present invention is a combination of the component (A) fucoxanthin and brown algae containing fucoxanthin and the component (B) gymnema and / or peppermint, so that UCP1 in white cells caused by fucoxanthin is used. Expression improves synergistically and exhibits a high slimming effect.
本発明の痩身用組成物は、成分（Ａ）フコキサンチン及びフコキサンチンを含有する褐藻類と、成分（Ｂ）ギムネマ及び／又はペパーミントを併用して用いる。これらの成分に関し、個々に説明する。 The slimming composition of the present invention uses component (A) fucoxanthin and brown algae containing fucoxanthin in combination with component (B) gymnema and / or peppermint. These components will be described individually.
本発明で用いるフコキサンチン（Ｆｕｃｏｘａｎｔｈｉｎ）は、下記化学式（１）で表されるカロテノイドの一つであり、褐藻やその他の不等毛藻に存在して茶色-オリーブ色を呈するとともに、葉緑体において光合成の補助色素として機能している。特に、褐藻類中のカロテノイドのほぼ１００％がフコキサンチンであるといわれている。 Fucoxanthin used in the present invention is one of the carotenoids represented by the following chemical formula (1), is present in brown algae and other unequal hairy algae and exhibits a brown-olive color, and also has a chloroplast. Functions as an auxiliary dye for photosynthesis. In particular, almost 100% of carotenoids in brown algae are said to be fucoxanthin.
本発明においては、精製されたフコキサンチンを用いても、フコキサンチンを含有する褐藻若しくはその抽出物を用いても良い。 In the present invention, purified fucoxanthin may be used, or brown algae containing fucoxanthin or an extract thereof may be used.
フコキサンチンを含有する褐藻類としては、特に限定されないが、例えばモズク科（Spermatochnaceae）モズク（イトモズク，Nemacystus decipiens）、オキナワモズク（Cladosiphon okamuranus T.;Eudesme virescens J.AG.）、コンブ科（Laminariaceae）マコンブ（Laminaria japonica）、アラメ（Eisenia bicyclis）、チガイソ科（Alariaceae）ワカメ（Undaria pinnatifida）、ホンダワラ科（Sargassaceae）ホンダワラ（Sargassum fulvellum）、ヒジキ（Sargassum fusiforme）等が例示される。これらの中でもフコキサンチンの含有量の点からマコンブを用いることが最も好ましい。 The brown algae containing fucoxanthin are not particularly limited. For example, Spermatochnaceae mozuku (Nemacystus decipiens), Okinawa mozuku (Cladosiphon okamuranus T.; Eudesme virescens J.AG.), Kombu (Laminariaceae) Examples include Macombu (Laminaria japonica), Alamece (Eisenia bicyclis), Chileaceae (Alariaceae) wakame (Undaria pinnatifida), Honda (Sargassaceae) Honda (Sargassum fulvellum), and hydrangea (Sargassum fusiforme). Among these, it is most preferable to use macombu in view of the content of fucoxanthin.
本発明において用いるギムネマは、ガガイモ科ホウライアオカズラ属に属する常緑のつる性植物で、熱帯地方を中心に２５種ほどが分布する。本発明においては、ホウライアオカズラ属植物であれば特に限定されないが、原料の供給の面からギムネマシルベストリス（Gymnema sylvestris R.Br.）を用いることが好ましい。使用部位は、特に限定されないが、葉及び／又は茎を用いることが一般的である。 Gymnema used in the present invention is an evergreen climbing plant belonging to the genus Horaiaokazura, and about 25 species are distributed mainly in the tropical region. In the present invention, the plant is not particularly limited as long as it is a plant belonging to the genus Holya quail, but Gymnema sylvestris R. Br. Is preferably used from the viewpoint of supply of raw materials. The use site is not particularly limited, but it is common to use leaves and / or stems.
本発明で用いるペパーミント（Mentha arvensis L. var. piperascens Malin.）は、シソ科（Labiatae）に属する多年草で、その同属植物である、セイヨウハッカ（Mentha piperita L.）、ミドリハッカ（Mentha viridis L.）を用いることもできる。ペパーミントは、葉，茎，花等各部位を用いることができるが、地上部の全体若しくは葉を用いることが好ましい。 Peppermint (Mentha arvensis L. var. Piperascens Malin.) Used in the present invention is a perennial belonging to the Labiatae family, and is a plant belonging to the same genus, Mentha piperita L., Mentha viridis L. Can also be used. Peppermint can use various parts such as leaves, stems, flowers, etc., but it is preferable to use the whole ground part or leaves.
本発明の痩身用組成物において、上記の藻類、植物は、そのまま用いることもできるが、溶媒による抽出物を用いることもできる。抽出溶媒としては、水の他、メタノール、エタノール、プロパノール、イソプロパノール等の低級アルコール、１、３−ブチレングリコール、プロピレングリコール、ジプロピレングリコール、グリセリン等の多価アルコール、エチルエーテル、プロピルエーテル等のエーテル類、酢酸ブチル、酢酸エチル等のエステル類、アセトン、エチルメチルケトン等のケトン類などの溶媒を用いることができ、これらより１種又は２種以上を選択して用いる。また、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等を用いてもよい。さらに、水や二酸化炭素、エチレン、プロピレン、エタノール、メタノール、アンモニアなどの１種又は２種以上の超臨界流体や亜臨界流体を用いてもよい。また、オートクレーブなどを用いて、加圧下で抽出することも可能である。 In the composition for slimming of the present invention, the algae and plants can be used as they are, but an extract using a solvent can also be used. Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol and glycerin, ethers such as ethyl ether and propyl ether. And solvents such as esters such as butyl acetate and ethyl acetate, and ketones such as acetone and ethyl methyl ketone can be used, and one or more of these can be selected and used. Further, physiological saline, phosphate buffer, phosphate buffered saline, or the like may be used. Furthermore, you may use 1 type, or 2 or more types of supercritical fluids and subcritical fluids, such as water, a carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia. It is also possible to extract under pressure using an autoclave or the like.
植物の上記溶媒による抽出物は、そのままでも使用することができるが、濃縮、乾固した物を水や極性溶媒に再度溶解して使用することもでき、これらの生理作用を損なわない範囲で脱色、脱臭、脱塩等の精製処理やカラムクロマトグラフィー等による分画処理を行った後に用いてもよい。植物の前記抽出物やその処理物及び分画物は、各処理及び分画後に凍結乾燥し、用時に溶媒に溶解して用いることもできる。 The plant extract of the above solvent can be used as it is, but the concentrated and dried product can be used again by dissolving it in water or a polar solvent. Alternatively, it may be used after purification treatment such as deodorization or desalting, or fractionation treatment by column chromatography or the like. The said extract of plant, its processed material, and a fraction can also be lyophilized | freeze-dried after each process and fractionation, and can also be used after melt | dissolving in a solvent at the time of use.
本発明の痩身用組成物は、皮膚に外用、経口摂取等の手段で投与することが可能であり、化粧料、食品、飲料、あるいは医薬品などに応用することが可能である。 The slimming composition of the present invention can be administered to the skin by means such as external application or ingestion, and can be applied to cosmetics, foods, beverages or pharmaceuticals.
さらに実施例により、本発明の特徴について詳細に説明する。まず、フコキサンチンとギムネマ、ペパーミントを併用した際のＵＣＰ１発現促進作用の評価について記載する。 Further, the features of the present invention will be described in detail by way of examples. First, it describes about evaluation of the UCP1 expression promotion effect at the time of using fucoxanthin, gymnema, and peppermint together.
（試料）
１．フコキサンチン
オリザ油化株式会社製、商品名フコキサンチン−ＷＳＰＣ０．１を用いた。
２．ギムネマ抽出物
ギムネマシルベストリス（Gymnema sylvestris R.Br.）の茎を乾燥させて粉砕し、サンプル質量の５０倍量の５０容量％エタノール水溶液を加えて攪拌しながら３時間抽出した後、ろ過により不溶物を取り除いた。減圧濃縮後凍結乾燥を行って、ギムネマ抽出物を得た。得られたギムネマ抽出物を試料として用いた。
３．ペパーミント抽出物
丸善製薬社製ペパーミント抽出液ＬＡを用いた。
(sample)
1. Fucoxanthin Oriza Yuka Co., Ltd. product name Fucoxanthin-WSPC0.1 was used.
2. Gymnema extract The stem of Gymnema sylvestris R.Br. is dried and pulverized, 50% by volume of 50% by volume aqueous ethanol solution is added and extracted for 3 hours with stirring, and then insoluble by filtration. The thing was removed. After concentration under reduced pressure, freeze drying was performed to obtain a Gymnema extract. The obtained Gymnema extract was used as a sample.
3. Peppermint extract Peppermint extract LA manufactured by Maruzen Pharmaceutical Co., Ltd. was used.
ＵＣＰ１発現促進作用評価
（１）ヒト白色脂肪細胞の培養とｃＤＮＡの調製
皮下脂肪由来正常ヒト前駆脂肪細胞を１ウェル当り１．０×１０4個となるように９６ウェルマイクロプレートに播種した。播種培地にはＰＧＭ培地（１０％ＦＢＳ，２ｍＭ Ｌ−ｇｌｕｔａｍｉｎｅ，１００ｕｎｉｔｓ／ｍＬ Ｐｅｎｉｃｉｌｌｉｎｅ，１００μｇ／ｍＬ Ｓｔｒｅｐｔｏｍｙｃｉｎｅ含有）を用いた。２４時間培養後、表１に示した濃度に調整した試料を添加したＰＧＭ分化用培地（１０μｇ／ｍＬインシュリン，１μＭ Ｄｅｘａｍｅｔｈａｓｏｎｅ，２００μＭ Ｉｎｄｏｍｅｔｈａｃｉｎ，５００μ ＭＩｓｏｂｕｔｙｌｍｅｔｈｙｌｘａｎｔｈｉｎｅ含有）に交換し、脂肪細胞への分化誘導を行った。分化誘導開始後、コントロール群が成熟して細胞内に多数の脂肪滴が蓄積されるまで、１４日間培養した。さらに、適当な濃度のサンプル（５０μＬ／ｗｅｌｌ）を培地へ添加し、２４時間培養した。ｍＲＮＡの抽出及びｃＤＮＡ合成にはＳｕｐｅｒＳｃｒｉｐｔＩＩＩ ｃｅｌｌ ｄｉｒｅｃｔ ｃＤＮＡ Ｓｙｎｔｈｅｓｉｓ Ｓｙｓｔｅｍ（Ｉｎｖｉｔｒｏｇｅｎ社製キット）を使用した。
（２）ＵＣＰ１ｍＲＮＡ発現量の測定
上記（１）で得られたｃＤＮＡをテンプレートとし、ｒｅａｌ−ｔｉｍｅ ＰＣＲ法によりＵＣＰ１のｍＲＮＡ発現量を測定した。評価機器としてＡｐｐｌｉｅｄ Ｂｉｏｓｙｓｔｅｍｓ ７９００ＨＴ Ｆａｓｔ リアルタイムＰＣＲシステム（Ａｐｐｌｉｅｄ Ｂｉｏｓｙｓｔｅｍｓ Ｊａｐａｎ社製）を用いた。試薬にはＳＹＢＲ（登録商標）Ｐｒｅｍｉｘ Ｅｘ Ｔａｑ ＩＩ（タカラバイオ社製）を、ＵＣＰ１センス側プライマー５’−ＡＣＴＴＧＧＴＧＴＣＧＧＣＴＣＴＴＡＴＣＧ−３’及びアンチセンス側プライマー５’−ＡＧＧＡＴＣＣＡＡＧＴＣＧＣＡＡＧＡＡＧＧ−３’若しくはＧＡＰＤＨのセンス側プライマー５’−ＣＣＡＣＴＣＣＴＣＣＡＣＣＴＴＴＧＡＣＧ−３’及びアンチセンス側プライマー５’−ＣＡＣＣＣＴＧＴＴＧＣＴＧＴＡＧＣＣＡＡ−３’を用いた。ＵＰＣ１の測定値をＧＡＰＤＨの測定値で補正し、試料未添加の場合の値をコントロールとして試料添加によるＵＣＰ１の発現量を相対比較した。
Evaluation of UCP1 expression promoting action (1) Culture of human white adipocytes and preparation of cDNA Subcutaneous adipose-derived normal human preadipocytes were seeded in a 96-well microplate so that the number was 1.0 × 10 4 per well. PGM medium (10% FBS, 2 mM L-glutamine, 100 units / mL Penicillin, containing 100 μg / mL Streptomycin) was used as the seeding medium. After culturing for 24 hours, the medium was replaced with a PGM differentiation medium (containing 10 μg / mL insulin, 1 μM Dexamethasone, 200 μM Indomethacin, 500 μMisobutymethylxanthine) containing a sample adjusted to the concentration shown in Table 1 to induce differentiation into adipocytes. It was. After initiation of differentiation, the cells were cultured for 14 days until the control group matured and many lipid droplets accumulated in the cells. Furthermore, a sample (50 μL / well) with an appropriate concentration was added to the medium and cultured for 24 hours. Superscript III cell direct cDNA Synthesis System (Invitrogen kit) was used for mRNA extraction and cDNA synthesis.
(2) Measurement of UCP1 mRNA expression level Using the cDNA obtained in (1) above as a template, UCP1 mRNA expression level was measured by real-time PCR. Applied Biosystems 7900HT Fast real-time PCR system (Applied Biosystems Japan) was used as an evaluation instrument. As a reagent, SYBR (registered trademark) Premix Ex Taq II (manufactured by Takara Bio Inc.), UCP1 sense-side primer 5′-ACTTGGTGTCGCGCTTTATCG-3 ′ and antisense-side primer 5′-AGGATCCAAGTCGCAAGAAGG-3 ′ or GAPDH sense-side primer 5 '-CCACTCCTCCCACTTTGACG-3' and antisense-side primer 5'-CACCCTGTGCTGTAGCCAA-3 'were used. The measured value of UPC1 was corrected with the measured value of GAPDH, and the expression level of UCP1 by the addition of the sample was relatively compared using the value when the sample was not added as a control.
表１に示したとおり、フコキサンチンと、ギムネマ抽出物若しくはペパーミント抽出物を併用することにより、それぞれを単独で用いたときと比較して、相乗的なＵＣＰ１発現量の向上が認められた。 As shown in Table 1, by using fucoxanthin in combination with a gymnema extract or peppermint extract, a synergistic improvement in UCP1 expression was observed compared to when each was used alone.
続いて、上述のフコキサンチンと、ギムネマ抽出物若しくはペパーミント抽出物を併用した皮膚外用剤と食品の処方例を示す。 Then, the prescription example of the skin external preparation and foodstuff which used the above-mentioned fucoxanthin and Gymnema extract or peppermint extract together is shown.
［処方例１］乳液
（１）スクワラン １０．０（重量％）
（２）メチルフェニルポリシロキサン ４．０
（３）水素添加パーム核油 ０．５
（４）水素添加大豆リン脂質 ０．１
（５）モノステアリン酸ポリオキシエチレン
ソルビタン（２０Ｅ．Ｏ．） １．３
（６）モノステアリン酸ソルビタン １．０
（７）グリセリン ４．０
（８）パラオキシ安息香酸メチル ０．１
（９）カルボキシビニルポリマー ０．１５
（10）精製水 ５７．８５
（11）アルギニン（１重量％水溶液） ２０．０
（12）フコキサンチン ０．５
（13）ギムネマ抽出物 ０．５
製法：（１）〜（６）の油相成分を８０℃にて加熱溶解する。一方（７）〜（10）の水相成分を８０℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。乳化終了後、冷却を開始し、（11）〜（13）を順次加え、均一に混合する。
[Formulation Example 1] Emulsion (1) Squalane 10.0 (wt%)
(2) Methylphenylpolysiloxane 4.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Polyoxyethylene monostearate
Sorbitan (20E.O.) 1.3
(6) Sorbitan monostearate 1.0
(7) Glycerin 4.0
(8) Methyl paraoxybenzoate 0.1
(9) Carboxyvinyl polymer 0.15
(10) Purified water 57.85
(11) Arginine (1 wt% aqueous solution) 20.0
(12) Fucoxanthin 0.5
(13) Gymnema extract 0.5
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After the emulsification is completed, cooling is started, and (11) to (13) are sequentially added and mixed uniformly.
［処方例２］化粧水
（１）エタノール １５．０（重量％）
（２）ポリオキシエチレン（４０Ｅ．Ｏ．）硬化ヒマシ油 ０．３
（３）香料 ０．１
（４）精製水 ８２．３８
（５）クエン酸 ０．０２
（６）クエン酸ナトリウム ０．１
（７）グリセリン １．０
（８）ヒドロキシエチルセルロース ０．１
（９）フコキサンチン ０．５
（10）ペパーミント抽出物 ０．５
製法：（１）に（２）及び（３）を溶解する。溶解後、（４）〜（８）を順次添加した後、十分に攪拌し、（９）、（10）を加え、均一に混合する。
[Prescription Example 2] Lotion (1) Ethanol 15.0 (wt%)
(2) Polyoxyethylene (40E.O.) hydrogenated castor oil 0.3
(3) Fragrance 0.1
(4) Purified water 82.38
(5) Citric acid 0.02
(6) Sodium citrate 0.1
(7) Glycerin 1.0
(8) Hydroxyethyl cellulose 0.1
(9) Fucoxanthin 0.5
(10) Peppermint extract 0.5
Production method: (2) and (3) are dissolved in (1). After dissolution, (4) to (8) are sequentially added, and then sufficiently stirred, and (9) and (10) are added and mixed uniformly.
［処方例３］クリーム
（１）スクワラン １０．０（重量％）
（２）ステアリン酸 ２．０
（３）水素添加パーム核油 ０．５
（４）水素添加大豆リン脂質 ０．１
（５）セタノール ３．６
（６）親油型モノステアリン酸グリセリン ２．０
（７）グリセリン １０．０
（８）パラオキシ安息香酸メチル ０．１
（９）アルギニン（２０重量％水溶液） １５．０
（10）精製水 ４０．７
（11）カルボキシビニルポリマー（１重量％水溶液） １５．０
（12）フコキサンチン ０．４
（13）ペパーミント抽出物 ０．３
（14）ギムネマ抽出物 ０．３
製法：（１）〜（６）の油相成分を８０℃にて加熱溶解する。一方（７）〜（10）の水相成分を８０℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。乳化終了後、（11）を加え、冷却を開始し、４０℃にて（12）〜（14）を加え、均一に混合する。
[Prescription Example 3] Cream (1) Squalane 10.0 (% by weight)
(2) Stearic acid 2.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Cetanol 3.6
(6) Lipophilic glyceryl monostearate 2.0
(7) Glycerin 10.0
(8) Methyl paraoxybenzoate 0.1
(9) Arginine (20% by weight aqueous solution) 15.0
(10) Purified water 40.7
(11) Carboxyvinyl polymer (1% by weight aqueous solution) 15.0
(12) Fucoxanthin 0.4
(13) Peppermint extract 0.3
(14) Gymnema extract 0.3
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. (11) is added after completion | finish of emulsification, cooling is started, (12)-(14) is added at 40 degreeC, and it mixes uniformly.
［処方例４］水性ジェル
（１）カルボキシビニルポリマー ０．５（重量％）
（２）精製水 ８６．７
（３）水酸化ナトリウム（１０重量％水溶液） ０．５
（４）エタノール １０．０
（５）パラオキシ安息香酸メチル ０．１
（６）香料 ０．１
（７）フコキサンチン ０．４
（８）ペパーミント抽出物 ０．３
（９）ギムネマ抽出物 ０．３
（10）ポリオキシエチレン（６０Ｅ．Ｏ．）硬化ヒマシ油 ０．１
製法：（１）を（２）に加え、均一に攪拌した後、（３）を加える。均一に攪拌した後、（４）に予め溶解した（５）を加える。均一に攪拌した後、予め混合しておいた（６）〜（10）を加え、均一に攪拌混合する。
[Formulation Example 4] Aqueous gel (1) Carboxyvinyl polymer 0.5 (% by weight)
(2) Purified water 86.7
(3) Sodium hydroxide (10% by weight aqueous solution) 0.5
(4) Ethanol 10.0
(5) Methyl paraoxybenzoate 0.1
(6) Fragrance 0.1
(7) Fucoxanthin 0.4
(8) Peppermint extract 0.3
(9) Gymnema extract 0.3
(10) Polyoxyethylene (60E.O.) hydrogenated castor oil 0.1
Manufacturing method: (1) is added to (2), and after stirring uniformly, (3) is added. After stirring uniformly, (5) previously dissolved in (4) is added. After stirring uniformly, (6) to (10) previously mixed are added and stirred and mixed uniformly.
［処方例５］温感ジェル
（１）グリセリン ９７．８（質量％）
（２）カルボキシビニルポリマー ０．５
（３）精製水 ０．５
（４）香料 ０．１
（５）ポリオキシエチレン（６０Ｅ．Ｏ．）硬化ヒマシ油 ０．１
（７）フコキサンチン ０．４
（８）ペパーミント抽出物 ０．３
（９）ギムネマ抽出物 ０．３
製法：全成分を均一に混合攪拌する。
[Prescription Example 5] Warm gel (1) Glycerin 97.8 (% by mass)
(2) Carboxyvinyl polymer 0.5
(3) Purified water 0.5
(4) Fragrance 0.1
(5) Polyoxyethylene (60E.O.) hydrogenated castor oil 0.1
(7) Fucoxanthin 0.4
(8) Peppermint extract 0.3
(9) Gymnema extract 0.3
Production method: All components are mixed and stirred uniformly.
［処方例６］パック
（１）精製水 ６２．９(重量％)
（２）ポリビニルアルコール １２．０
（３）エタノール １７．０
（４）グリセリン ５．０
（５）ポリエチレングリコール（平均分子量１０００） ２．０
（６）フコキサンチン ０．４
（７）ペパーミント抽出物 ０．３
（８）ギムネマ抽出物 ０．３
（９）香料 ０．１
製法：（２）と（３）を混合し、８０℃に加温した後、８０℃に加温した（１）に溶解する。均一に溶解した後、（４）と（５）を加え、攪拌しながら冷却を開始する。４０℃まで冷却し、（６）〜（９）を加え、均一に混合する。
[Formulation Example 6] Pack (1) 62.9 (% by weight) purified water
(2) Polyvinyl alcohol 12.0
(3) Ethanol 17.0
(4) Glycerin 5.0
(5) Polyethylene glycol (average molecular weight 1000) 2.0
(6) Fucoxanthin 0.4
(7) Peppermint extract 0.3
(8) Gymnema extract 0.3
(9) Fragrance 0.1
Production method: (2) and (3) are mixed, heated to 80 ° C, and then dissolved in (1) heated to 80 ° C. After uniformly dissolving, add (4) and (5), and start cooling while stirring. Cool to 40 ° C., add (6) to (9) and mix uniformly.
［処方例７］錠剤
（１）フコキサンチン ４０．０（質量部）
（２）ペパーミント抽出物 ３０．０
（３）ギムネマ抽出物 ３０．０
（４）トウモロコシデンプン １５．０
（５）グリセリン脂肪酸エステル １２．０
（６）香料 １２．０
製法：（１）〜（６）を混合し、常法により打錠して、全量が６００ｍｇの錠剤を得た。
[Prescription Example 7] Tablet (1) Fucoxanthin 40.0 (parts by mass)
(2) Peppermint extract 30.0
(3) Gymnema extract 30.0
(4) Corn starch 15.0
(5) Glycerin fatty acid ester 12.0
(6) Fragrance 12.0
Production method: (1) to (6) were mixed and tableted by a conventional method to obtain a tablet having a total amount of 600 mg.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010012156A JP2011148741A (en) | 2010-01-22 | 2010-01-22 | Slimming composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010012156A JP2011148741A (en) | 2010-01-22 | 2010-01-22 | Slimming composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2011148741A true JP2011148741A (en) | 2011-08-04 |
Family
ID=44536101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010012156A Pending JP2011148741A (en) | 2010-01-22 | 2010-01-22 | Slimming composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2011148741A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63277627A (en) * | 1987-05-08 | 1988-11-15 | Nitto Electric Ind Co Ltd | Saccharide absorption suppressing composition |
| JP2001354517A (en) * | 2000-06-12 | 2001-12-25 | Nobiriteii Corporation:Kk | External preparation for skin |
| JP2003026585A (en) * | 2001-07-10 | 2003-01-29 | Maruzen Pharmaceut Co Ltd | Lipase inhibitor |
| JP2006016312A (en) * | 2004-06-30 | 2006-01-19 | Morishita Jintan Kk | Fat-metabolism improving composition |
| JP2008163014A (en) * | 2006-12-06 | 2008-07-17 | Kaneka Corp | 11beta-HSD1 INHIBITOR AND ITS USE |
| JP2008231057A (en) * | 2007-03-22 | 2008-10-02 | Hokkaido Univ | Neutral fat absorption regulating composition |
| JP2008291004A (en) * | 2007-04-26 | 2008-12-04 | Oriza Yuka Kk | Skin care composition |
| JP2010270021A (en) * | 2009-05-19 | 2010-12-02 | Oriza Yuka Kk | UCP gene expression promoter |
-
2010
- 2010-01-22 JP JP2010012156A patent/JP2011148741A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63277627A (en) * | 1987-05-08 | 1988-11-15 | Nitto Electric Ind Co Ltd | Saccharide absorption suppressing composition |
| JP2001354517A (en) * | 2000-06-12 | 2001-12-25 | Nobiriteii Corporation:Kk | External preparation for skin |
| JP2003026585A (en) * | 2001-07-10 | 2003-01-29 | Maruzen Pharmaceut Co Ltd | Lipase inhibitor |
| JP2006016312A (en) * | 2004-06-30 | 2006-01-19 | Morishita Jintan Kk | Fat-metabolism improving composition |
| JP2008163014A (en) * | 2006-12-06 | 2008-07-17 | Kaneka Corp | 11beta-HSD1 INHIBITOR AND ITS USE |
| JP2008231057A (en) * | 2007-03-22 | 2008-10-02 | Hokkaido Univ | Neutral fat absorption regulating composition |
| JP2008291004A (en) * | 2007-04-26 | 2008-12-04 | Oriza Yuka Kk | Skin care composition |
| JP2010270021A (en) * | 2009-05-19 | 2010-12-02 | Oriza Yuka Kk | UCP gene expression promoter |
Non-Patent Citations (2)
| Title |
|---|
| JPN6013053763; フコキサンチン , 20081019, ｐｐ．１-３２, オリザ油化株式会社 * |
| JPN6013053765; 食品と開発 Ｖｏｌ．２８， Ｎｏ．２, 19930201, ｐｐ．１０-１３ * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Madureira et al. | Applications of bioactive compounds extracted from olive industry wastes: A review | |
| CN104547045B (en) | A kind of leaf of Moringa compound granules and preparation method thereof | |
| JP5171097B2 (en) | Heparin-binding epidermal growth factor-like growth factor gene expression promoter containing plant extract | |
| JP6055667B2 (en) | Collagen production promoter | |
| JP2011088845A (en) | Involucrin expression inhibitor | |
| JP2008540582A (en) | System and method for promoting hair growth and improving hair and scalp health | |
| JP6280685B2 (en) | Tie2 activator, angiogenesis inhibitor, vascular maturation agent, vascular normalization agent, and vascular stabilization agent | |
| CN109806196A (en) | A kind of milky lotion and the method for preparing the milky lotion | |
| JP2008024622A (en) | Collagen type iv production promoter and basement membrane enhancer | |
| JP6861955B2 (en) | Hyaluronic acid synthesis accelerator | |
| JP2009185007A (en) | Promoting agent for production of keratinocyte growth factor | |
| JP2011148742A (en) | Cell activator and skin external preparation | |
| JP6377879B1 (en) | Topical skin preparation | |
| JP2011148741A (en) | Slimming composition | |
| JP5313064B2 (en) | Neutral fat accumulation promoter, breast augmentation | |
| JP6020155B2 (en) | Fibroblast growth promoter | |
| JP2009102284A (en) | Fibroblast growth factor-1 production promoter | |
| JP2016013981A (en) | Tubulin polymerization activity regulator, food and agent comprising the same, and method of producing tubulin polymerization activity regulator | |
| KR20170094632A (en) | Manufacturing method for hair loss prevention shampoos containing ginsenoside Rg2 | |
| JP6629271B2 (en) | Endo180 production promoter | |
| JP2008081440A (en) | Aromatase activity promoter | |
| JP2017078048A (en) | Cosmetics and drugs for promoting expression of hyaluronan synthase gene | |
| JP2007063207A (en) | Adiponectin production promoter | |
| JP2020002054A (en) | Aquaporin expression enhancer containing sasa veitchii extract preparation as active ingredient and healing promoter containing the same as well as production method thereof | |
| Liu et al. | Preparation, Physiological Activity and High-Value Applications of Fucoidan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120802 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131029 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131225 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140617 |